大行評級|高盛:首予藥明合聯“買入”評級 目標價41.7港元
高盛發表研究報吿,首次給予藥明合聯“買入”評級,指出該公司所在的ADC行業正在全球範圍迅速發展,ADC及生物共軛物作為新興藥物領域,可能會重塑腫瘤及其他領域的治療標準,相信可提供一個風險平衡的投資機會。根據藥明合聯在手訂單及資本支出計劃,高盛預測該公司2023至2025年銷售額年均複合增長率達到59%,核心淨利潤率預期從2023年的20.6%,增長至2025年24.1%,相應給予目標價41.7港元。高盛指,雖然ADC的長期潛力仍有待挖掘,但對CRDMO的短中期需求前景充滿信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.